{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:39:45Z","timestamp":1766050785543,"version":"3.44.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601"],"award-info":[{"award-number":["12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601","12601"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>International guidelines recommend germline genetic testing for men with metastatic prostate cancer. If offered to all patients by genetic healthcare professionals, there will be insufficient capacity to cope with the high patient numbers. In a mainstreaming pathway, non-genetic healthcare professionals (ngHCPs) discuss and order germline genetic testing instead of referring patients to genetic healthcare professionals. We aimed to evaluate the experience of ngHCPs with pre-test genetic counselling and to explore the feasibility from the ngHCPs\u2019 perspective.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We carried out a prospective cohort study in 15 hospitals in the Netherlands. All participating ngHCPs (i.e. urologists, medical oncologists, specialist nurses and nurse practitioners) completed an online training module of 45\u2009min. The ngHCPs completed a questionnaire both before the training and at three and nine months after it. Paired analyses were used to compare the first with the last questionnaires on attitude, confidence in the ability to discuss and order germline genetic testing, and perceived and actual knowledge of genetics and genetic testing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>167 ngHCPs were invited to participate of whom 69 completed the first questionnaire and started or completed the last one. They had a positive attitude towards offering genetic testing themselves. After nine months of providing pre-test genetic counselling, significantly more ngHCPs considered mainstreaming helpful (94% after versus 81% before, <jats:italic>p<\/jats:italic>\u2009=\u20090.01). Both perceived and actual knowledge increased significantly. Pre-test genetic counselling took less than 10\u2009minutes for 82% of ngHCPs and the majority (88%) were in favour of continuing the mainstream pathway. Only six participating ngHCPs considered mainstreaming possible without completing a training module beforehand.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>After completing a short online training module, ngHCPs feel well-prepared to discuss germline genetic testing with metastatic prostate cancer patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41391-024-00925-w","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T15:10:21Z","timestamp":1733411421000},"page":"789-794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7384-8043","authenticated-orcid":false,"given":"Michiel","family":"Vlaming","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margreet G. E. M.","family":"Ausems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2368-1326","authenticated-orcid":false,"given":"Lambertus A. L. M.","family":"Kiemeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Schijven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harm H. E.","family":"van Melick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Arjen","family":"Noordzij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-6586","authenticated-orcid":false,"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk G.","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J.","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart P.","family":"Wijsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reindert J. A.","family":"van Moorselaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart P. J.","family":"van Bezooijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard P.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martijn B.","family":"Busstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Pieter","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie G. J.","family":"Robbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin H. J.","family":"Doornweerd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eveline M. A.","family":"Bleiker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8002-1869","authenticated-orcid":false,"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"unstructured":"Cornford P, Tilki D, van den Bergh R, Briers E, Advocate EP, Eberli D, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG: Guidelines on Prostate Cancer (2024).","key":"925_CR1"},{"unstructured":"National Comprehensive Cancer Network. Prostate cancer (Version 4.2024).","key":"925_CR2"},{"key":"925_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO Guideline (2023). J Urol. 2023;209:1082\u201390.","journal-title":"J Urol"},{"key":"925_CR4","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J De Bono","year":"2020","unstructured":"De Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102.","journal-title":"N Engl J Med"},{"key":"925_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med. 2023;388:719\u201332.","journal-title":"N Engl J Med"},{"key":"925_CR6","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383:2345\u201357.","journal-title":"N Engl J Med"},{"key":"925_CR7","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/jnci\/djm203","volume":"99","author":"YC Tai","year":"2007","unstructured":"Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99:1811\u20134.","journal-title":"J Natl Cancer Inst"},{"key":"925_CR8","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.21.02112","volume":"40","author":"S Li","year":"2022","unstructured":"Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022;40:1529\u201342.","journal-title":"J Clin Oncol"},{"key":"925_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","volume":"14","author":"MJ Hall","year":"2021","unstructured":"Hall MJ, Bernhisel R, Hughes E, Larson K, Rosenthal ET, Singh NA, et al. Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers. Cancer Prev Res. 2021;14:433\u201340.","journal-title":"Cancer Prev Res"},{"key":"925_CR10","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3390\/cells9122675","volume":"9","author":"L Stolarova","year":"2020","unstructured":"Stolarova L, Kleiblova P, Janatova M, Soukupova J, Zemankova P, Macurek L, Kleibl Z. CHEK2 germline variants in cancer predisposition: stalemate rather than checkmate. Cells. 2020;9:2675.","journal-title":"Cells"},{"key":"925_CR11","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3390\/cancers14041059","volume":"14","author":"K Bokkers","year":"2022","unstructured":"Bokkers K, Vlaming M, Engelhardt EG, Zweemer RP, van Oort IM, Kiemeney LA, et al. The feasibility of implementing mainstream germline genetic testing in routine cancer care\u2014a systematic review. Cancers. 2022;14:1059.","journal-title":"Cancers"},{"key":"925_CR12","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1245\/s10434-023-13229-5","volume":"30","author":"K Bokkers","year":"2023","unstructured":"Bokkers K, Bleiker E, Aalfs C, van Dalen T, Velthuizen M, Duijveman P, et al. Surgical oncologists and nurses in breast cancer care are ready to provide pre-test genetic counseling. Ann Surgical Oncol. 2023;30:3248\u201358.","journal-title":"Ann Surgical Oncol"},{"doi-asserted-by":"crossref","unstructured":"Bokkers K, Zweemer RP, Koudijs MJ, Stehouwer S, Velthuizen ME, Bleiker E, Ausems MG. Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer. Fam Cancer. 2021;21:1\u201310.","key":"925_CR13","DOI":"10.1007\/s10689-021-00277-7"},{"key":"925_CR14","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1200\/JCO.2017.76.2781","volume":"36","author":"N Colombo","year":"2018","unstructured":"Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, et al. Evaluation of a streamlined oncologist-led brca mutation testing and counseling model for patients with ovarian cancer. J Clin Oncol. 2018;36:1300\u20137.","journal-title":"J Clin Oncol"},{"key":"925_CR15","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41431-020-0692-y","volume":"28","author":"N Flaum","year":"2020","unstructured":"Flaum N, Morgan RD, Burghel GJ, Bulman M, Clamp AR, Hasan J, et al. Mainstreaming germline BRCA1\/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. Eur J Hum Genet. 2020;28:1541\u20137.","journal-title":"Eur J Hum Genet"},{"key":"925_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep29506","volume":"6","author":"A George","year":"2016","unstructured":"George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep. 2016;6:1\u20138.","journal-title":"Sci Rep"},{"key":"925_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ygyno.2020.05.001","volume":"158","author":"M Gleeson","year":"2020","unstructured":"Gleeson M, Kentwell M, Meiser B, Do J, Nevin S, Taylor N, et al. The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients. Gynecol Oncol. 2020;158:431\u20139.","journal-title":"Gynecol Oncol"},{"key":"925_CR18","doi-asserted-by":"publisher","first-page":"e194428","DOI":"10.1001\/jamanetworkopen.2019.4428","volume":"2","author":"Z Kemp","year":"2019","unstructured":"Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, et al. Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer. JAMA Netw Open. 2019;2:e194428.","journal-title":"JAMA Netw Open"},{"key":"925_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ygyno.2020.07.027","volume":"159","author":"CB Powell","year":"2020","unstructured":"Powell CB, Laurent C, Ciaravino G, Garcia C, Han L, Hoodfar E, et al. Streamlining genetic testing for women with ovarian cancer in a Northern California health care system. Gynecol Oncol. 2020;159:221\u20138.","journal-title":"Gynecol Oncol"},{"key":"925_CR20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/jmedgenet-2020-107416","volume":"59","author":"S-Y Yoon","year":"2022","unstructured":"Yoon S-Y, Wong SW, Lim J, Ahmad S, Mariapun S, Padmanabhan H, et al. Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes. J Med Genet. 2022;59:220\u20139.","journal-title":"J Med Genet"},{"key":"925_CR21","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1200\/OP.20.00399","volume":"17","author":"T Scheinberg","year":"2021","unstructured":"Scheinberg T, Goodwin A, Ip E, Linton A, Mak B, Smith DP, et al. Evaluation of a mainstream model of genetic testing for men with prostate cancer. JCO Oncol Pract. 2021;17:e204\u2013e216.","journal-title":"JCO Oncol Pract"},{"doi-asserted-by":"crossref","unstructured":"Hamilton JG, Symecko H, Spielman K, Breen K, Mueller R, Catchings A. et al. Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. Genetics Med. 2021;23:1\u20139.","key":"925_CR22","DOI":"10.1038\/s41436-021-01262-2"},{"key":"925_CR23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1097\/JU.0000000000002865","volume":"208","author":"SM Abusamra","year":"2022","unstructured":"Abusamra SM, Solorzano MA, Luke M, Quarles J, Jacobs MF, Das S, et al. Satisfaction with clinician-led germline genetic counseling in patients with prostate cancer. J Urol. 2022;208:1007\u201317.","journal-title":"J Urol"},{"key":"925_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10429-2","volume":"22","author":"M Vlaming","year":"2022","unstructured":"Vlaming M, Bleiker EMA, van Oort IM, Kiemeney LALM, Ausems MGEM. Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study. BMC Cancer. 2022;22:1365.","journal-title":"BMC Cancer"},{"key":"925_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/ajmg.a.10868","volume":"116","author":"E Claes","year":"2003","unstructured":"Claes E, Evers\u2010Kiebooms G, Boogaerts A, Decruyenaere M, Denayer L, Legius E. Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet Part A. 2003;116:11\u201319.","journal-title":"Am J Med Genet Part A"},{"unstructured":"National Comprehensive Cancer Network. Prostate cancer (Version 1.2018).","key":"925_CR26"},{"unstructured":"Mottet N, Cornford P, van den Bergh R, Briers E, De Santis M, Gillessen S. et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG: Guidelines on Prostate Cancer (2021).","key":"925_CR27"},{"key":"925_CR28","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1200\/JCO.1996.14.5.1730","volume":"14","author":"American Society of Clinical Oncology.","year":"1996","unstructured":"American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol. 1996;14:1730\u20136.","journal-title":"J Clin Oncol"},{"key":"925_CR29","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/pros.24172","volume":"81","author":"S Loeb","year":"2021","unstructured":"Loeb S, Li R, Sanchez Nolasco T, Byrne N, Cheng HH, Becker D, et al. Barriers and facilitators of germline genetic evaluation for prostate cancer. Prostate. 2021;81:754\u201364.","journal-title":"Prostate"},{"key":"925_CR30","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1200\/JCO.2014.55.4576","volume":"32","author":"W Eijzenga","year":"2014","unstructured":"Eijzenga W, Aaronson NK, Hahn DE, Sidharta GN, van der Kolk LE, Velthuizen ME, et al. Effect of routine assessment of specific psychosocial problems on personalized communication, counselors\u2019 awareness, and distress levels in cancer genetic counseling practice: a randomized controlled trial. J Clin Oncol. 2014;32:2998\u20133004.","journal-title":"J Clin Oncol"},{"key":"925_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.breast.2023.03.017","volume":"69","author":"K Bokkers","year":"2023","unstructured":"Bokkers K, Bleiker E, Velthuizen M, Koelemij R, Burgmans J, Klinkenbijl J, et al. Patients\u2019 experiences with pre-test genetic counseling provided by breast cancer healthcare professionals: results from a large prospective multicenter study. Breast. 2023;69:349\u201357.","journal-title":"Breast"},{"key":"925_CR32","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1200\/PO.21.00238","volume":"5","author":"J Russo","year":"2021","unstructured":"Russo J, McDougall C, Bowler N, Shimada A, Gross L, Hyatt C, et al. Pretest genetic education video versus genetic counseling for men considering prostate cancer germline testing: a patient-choice study to address urgent practice needs. JCO Precis Oncol. 2021;5:1377\u201386.","journal-title":"JCO Precis Oncol"},{"key":"925_CR33","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00552","volume":"8","author":"S Loeb","year":"2024","unstructured":"Loeb S, Keith SW, Cheng HH, Leader AE, Gross L, Sanchez Nolasco T, et al. TARGET: a randomized, noninferiority trial of a pretest, patient-driven genetic education webtool versus genetic counseling for prostate cancer germline testing. JCO Precis Oncol. 2024;8:e2300552.","journal-title":"JCO Precis Oncol"},{"key":"925_CR34","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.1200\/OP.22.00638","volume":"19","author":"DH Kwon","year":"2023","unstructured":"Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, et al. Implementation of a telehealth genetic testing station to deliver germline testing for men with prostate cancer. JCO Oncol Pract. 2023;19:e773\u2013e783.","journal-title":"JCO Oncol Pract"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00925-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00925-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00925-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T01:27:27Z","timestamp":1757122047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-024-00925-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1038\/s41391-024-00925-w","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"type":"print","value":"1365-7852"},{"type":"electronic","value":"1476-5608"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The Medical Ethics Committee of UMC Utrecht ruled that the Dutch Medical Research Involving Human Subjects Act did not apply to this study. Participation in the initial questionnaire prior to the online training module, completion of the online training module, and completion of the final questionnaire were considered as implied consent; therefore, no signature was required for participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}